Drug intelligence / Profile preview

somatropin (ALTU-238)

Development stage: Phase 2
Lead developer: Ajinomoto Bio-Pharma Services
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

ALTU-238 is a long-acting subcutaneous formulation of recombinant human growth hormone in a ready-to-use liquid suspension. It employs Altus Pharmaceuticals' proprietary protein crystallization and formulation technology that preserves the structure of the human growth hormone molecule without requiring polymers or encapsulation. This technology enables administration through a fine gauge needle. ALTU-238 was designed as a once-weekly treatment for growth hormone deficiencies in both pediatric and adult patients, potentially improving compliance compared to daily injections required by standard treatments.

Other names: crystalline somatropinweekly somatropin Altus

Targets

GHR (Growth hormone receptor)

Beyond the preview

Go deeper on somatropin (ALTU-238).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on somatropin (ALTU-238).

Explore the full profile